Zolbetuximab plus chemo in CLDN18.2-positive metastatic pancreatic cancer does not improve OS
Zolbetuximab plus chemo in CLDN18.2-positive metastatic pancreatic cancer does not improve OS
Talquetamab plus daratumumab with or without pomalidomide improves PFS in r/r multiple myeloma
Defining breast cancer quality care around the globe
The evolving treatment landscape in immune thrombocytopenia
Highlights from APCCC 2026
ASCO 2026: Updates in bladder cancer
ASCO 2026: Updates in renal cancer
ASCO 2026: Updates in testicular, germ cell and rare genitourinary cancer
First-in-class switchable allogeneic CAR-T therapy shows promising activity in relapsed or refractory AML
Epcoritamab plus rituximab and lenalidomide improves outcomes across follicular lymphoma subgroups
Epcoritamab improves progression-free survival in relapsed or refractory large B-cell lymphoma
Mezigdomide plus carfilzomib dexamethasone improves PFS in R/R multiple myeloma